Psychiatric Morbidity in Ketamine Users Attending Counselling and Youth Outreach Services

REFERENCES

• Tamanna S, Geraci SA. Major sleep disorders among women: (women's health series). South Med J. 2013;106:470–478.
   PubMed Web of Science ®Google Scholar
• Central Registry of Drug Abuse. Drug Abusers for 2002–2011 by Age by Sex by Common Type of Drugs. Hong Kong: Hong Kong Narcotics Division; 2012.
   Google Scholar
• Elwood P, Hack M, Pickering J, Hughe J, Gallacher J. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health. 2006;90:69–73.
   Web of Science ®Google Scholar
• Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110:1762–1766.
   PubMed Web of Science ®Google Scholar
• Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use 1975–2013. Available at: http://www.monitoringthefuture.org. Accessed April 3, 2014.
   Google Scholar
• Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use 1975–2012. Available at: http://www.monitoringthefuture.org. Accessed August 17, 2013.
   Google Scholar
• Eccleston C, Crombez G. Pain demands attention: a cognitive-affective model of the interruptive function of pain. Psychol Bull. 1999;125:356–366.
   PubMed Web of Science ®Google Scholar
• Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke. 2000;31:12223–11229.
   Google Scholar
• Mayer G, Jennum P, Riemann D, Dauvilliers Y. Insomnia in central neurologic diseases—occurrence and management. Sleep Med Rev. 2011;15:369–378.
   PubMed Web of Science ®Google Scholar
• National Stroke Foundation. Pain Management After Stroke. Melbourne, Australia, National Stroke Foundation National Office; 2012.
   Google Scholar
• Morgan C, Curran HV. Ketamine use: a review. Addiction. 2011;107:27–38.
   PubMed Web of Science ®Google Scholar
• Abi-Saab WM, D'souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 1998;31(Suppl 2):104–109.
   PubMed Web of Science ®Google Scholar
• Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156:1646–1649.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Belger A, D'souza DC, Anand A, et al. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology. 1999;21:S143–S157.
   Web of Science ®Google Scholar
• Krystal JH, D'souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999;7:125–143.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985–994.
   PubMed Web of Science ®Google Scholar
• Lahti AC, Holcomb HH, Gao X, Tamminga CA. NMDA sensitive glutamate antagonism: a human model for psychosis. Neuropsychopharmacology. 1999;21:S158–S169.
   Google Scholar
• Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455–467.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301–307.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–118.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl). 1998;135:213–229.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci. 2003;1003:176–184.
   PubMed Web of Science ®Google Scholar
• Novy DM, Nelson DV, Francis DJ, Turk DC. Perspectives of chronic pain: an evaluative comparison of restrictive and comprehensive models. Psychol Bull. 1995;118:238–247.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
   PubMed Web of Science ®Google Scholar
• Aan Het RotM, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–145.
   PubMed Web of Science ®Google Scholar
• Curran HV, Morgan CJ. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction. 2000;95:575–590.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction. 2004;99:1450–1461.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105:121–133.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Duffin S, Hunt S, Monaghan L, Mason O, Curran HV. Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis (‘skunk’) or on cocaine. Pharmacopsychiatry. 2012;45:269–274.
   PubMed Web of Science ®Google Scholar
• Tang A, Liang HJ, Ungvari GS, Tang WK. Referral patterns and clinical characteristics of subjects referred to substance abuse clinic of a regional hospital in Hong Kong. East Asian Arch Psychiatry. 2011;21:22–27.
   Google Scholar
• Tang A, Cheung RY, Liang HJ, Ungvari GS, Tang WK. Psychiatric morbidity at a female residential drug treatment centre in Hong Kong. East Asian Arch Psychiatry. 2011;21:28–31.
   Google Scholar
• Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;28:893–907.
   Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area study. JAMA. 1990;264:2511–2518.
   PubMed Web of Science ®Google Scholar
• Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607–614.
   PubMed Web of Science ®Google Scholar
• Shek DT. Reliability and factorial structure of the Chinese version of the Beck Depression Inventory. J Clin Psychol. 1990;46:35–43.
   PubMed Web of Science ®Google Scholar
• Lee DT, Yip AS, Chiu HF, Leung TY, Chung TK. Screening for postnatal depression: are specific instruments mandatory? J Affect Disord. 2001;63:233–238.
   PubMed Web of Science ®Google Scholar
• Leung CM, Ho S, Kan CS, Hung CH, Chen CN. Evaluation of the Chinese version of the Hospital Anxiety and Depression Scale: a cross-cultural perspective. Int J Psychosom. 1993;40:29–34.
   PubMedGoogle Scholar
• Bunevicius R, Peceliuniene J, Mickuviene N, Bunevicius A, Pop V, Girdler S. Mood and thyroid immunity assessed by ultrasonographic imaging in a primary health care. J Affect Disord. 2007;97:85–90.
   PubMed Web of Science ®Google Scholar
• So E, Kam I, Leung CM, Pan A, Lam L. The Chinese-bilingual SCID-I/P Project: stage 2—reliability for anxiety disorders, adjustment disorders, and “no diagnosis”. Hong Kong J Psychiatry. 2003;13:19–25.
   Google Scholar
• So E, Kam I, Leung CM, Liu Z, Fong S. The Chinese-bilingual SCID-I/P Project: stage 1—reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry. 2003;13:7–18.
   Google Scholar
• Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the beck depression inventory. A review. Psychopathology. 1998;31:160–168.
   PubMed Web of Science ®Google Scholar
• Charney DA, Paraherakis AM, Negrete JC, Gill KJ. The impact of depression on the outcome of addictions treatment. J Subst Abuse Treat. 1998;15:123–130.
   PubMed Web of Science ®Google Scholar
• Curran GM, Kirchner JE, Worley M, Rookey C, Booth BM. Depressive symptomatology and early attrition from intensive outpatient substance use treatment. J Behav Health Serv Res. 2002;29:138–143.
   PubMed Web of Science ®Google Scholar
• Hesse M. The Beck Depression Inventory in patients undergoing opiate agonist maintenance treatment. Br J Clin Psychol. 2006;45:417–425.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
   PubMed Web of Science ®Google Scholar
• Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC183845/#__ffn_sectitle
   PubMedGoogle Scholar
• Corlett PR, Honey GD, Krystal JH, Fletcher PC. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology. 2011;36:294–315.
   PubMed Web of Science ®Google Scholar
• Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21:14–18.
   PubMed Web of Science ®Google Scholar
• Tortajada S, Herrero MJ, Domingo-Salvany A, et al. Psychiatric morbidity among cocaine and heroin users in the community. Adicciones. 2012;24:201–210.
   PubMed Web of Science ®Google Scholar
• Wu LT, Gersing K, Burchett B, Woody GE, Blaze DG. Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res. 2011;45:1453–1462.
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111.
   PubMed Web of Science ®Google Scholar
• Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord. 2013;147:416–420.
   PubMed Web of Science ®Google Scholar
• Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct. 2012;217:395–409.
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927.
   PubMed Web of Science ®Google Scholar
• Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005;162:2352–2359.
   PubMed Web of Science ®Google Scholar
• Liao Y, Tang J, Corlett PR, et al. Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry. 2011;69:42–28.
   PubMed Web of Science ®Google Scholar
• Liao Y, Tang J, Fornito A, et al. Alterations in regional homogeneity of resting-state brain activity in ketamine addicts. Neurosci Lett. 2012;522:36–40.
   PubMed Web of Science ®Google Scholar
• Liao Y, Tang J, Ma M, et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain. 2010;133:2115–2122.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Ketamine use: a review. Addiction. 2012;107:27–38.
   PubMed Web of Science ®Google Scholar
• Jansen K. Ketamine: Dreams and Realities. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies; 2004: 244.
   Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32–41.
   PubMed Web of Science ®Google Scholar
• Araos P, Vergara-Moragues E, Pedraz M, et al. Psychopathological comorbidity in cocaine users in outpatient treatment. Adicciones. 2014;26:15–26.
   PubMed Web of Science ®Google Scholar
• Chahua M, Sordo L, Molist G, et al. Depression in young regular cocaine users recruited in the community. Gac Sanit. 2014;28:155–159.
   PubMed Web of Science ®Google Scholar
• Rofael HZ, Abdel-Rahman MS. The role of ketamine on plasma cocaine pharmacokinetics in rat. Toxicol Lett. 2002;129:167–176.
   PubMed Web of Science ®Google Scholar
• Madhavan A, Argilli E, Bonci A, Whistler JL. Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area. J Neurosci. 2013;33:12329–12336.
   PubMed Web of Science ®Google Scholar
• Wakabayashi KT, Kiyatkin EA. Rapid changes in extracellular glutamate induced by natural arousing stimuli and intravenous cocaine in the nucleus accumbens shell and core. J Neurophysiol. 2012;108:285–299.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Johnston M, Terpstra K, Bureau Y. Cannabis and psychosis: neurobiology. Indian J Psychiatry. 2014;56:8–16.
   PubMed Web of Science ®Google Scholar
• Coscas S, Benyamina A, Reynaud M, Karila L. Psychiatric complications of cannabis use. Rev Prat. 2013;63:1426–1428.
   PubMedGoogle Scholar
• Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441–444.
   PubMed Web of Science ®Google Scholar
• Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80–86.
   PubMed Web of Science ®Google Scholar
• Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci U S A. 1989;86:9584–9587.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–816.
   PubMed Web of Science ®Google Scholar
• Bijl RV, De Graaf R, Ravelli A, Smit F, Vollebergh WA. Gender and age specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 2002;37:372–379.
   PubMed Web of Science ®Google Scholar
• Kolltveit S, Lange-Nielsen II, Thabet AA, et al. Risk factors for PTSD, anxiety, and depression among adolescents in gaza. J Trauma Stress. 2012;25:164–170.
   PubMed Web of Science ®Google Scholar
• De Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands mental health survey and incidence study. Am J Psychiatry. 2002;159:620–629.
   PubMed Web of Science ®Google Scholar
• Shrier LA, Harris SK, Kurland M, Knight JR. Substance use problems and associated psychiatric symptoms among adolescents in primary care. Pediatrics. 2003;111:e699–e705.
   PubMed Web of Science ®Google Scholar
• Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64:863–870.
   PubMed Web of Science ®Google Scholar
• Urbanoski KA, Rush BR, Wild TC, Bassani DG, Castel S. Use of mental health care services by Canadians with co-occurring substance dependence and mental disorders. Psychiatr Serv. 2007;58:962–969.
   PubMed Web of Science ®Google Scholar